Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethyl-EPA in Major Depressive Disorder
NCT00096798Phase 3Completed
- Sponsor
- National Center for Complementary and Integrative Health
- Start
- Sep 2001
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Ethyl-EPA with Placebo (2 arms). Primary endpoint: Alleviation of depressive symptoms at 8 weeks. Started Sep 2001; status: completed.
02
Drugs
Epadel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00096798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096798.